Bronchogenic carcinoma

This global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…

This study is for people with a specific type of lung cancer (EGFR-mutant) that has spread to other parts of the body after they finished a previous treatment (osimertinib). The goal is to see if combining osimertinib with chemotherapy can help control the cancer for longer. Abou…

This study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…

This phase 2 trial tests whether combining the immunotherapy drug cemiplimab with either chemotherapy or targeted radiation (SBRT) before surgery can eliminate or shrink non-small cell lung cancer more effectively. About 112 people with stage IB to III (N2) lung cancer will recei…

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…

This study looks at two standard treatments for early-stage lung cancer: surgery and a precise type of radiation called stereotactic radiotherapy. About 670 veterans with stage I non-small cell lung cancer will take part. The goal is to see which treatment leads to longer surviva…

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This study looks at whether a structured program can help more high-risk smokers get a first lung cancer screening with a CT scan. About 500 people aged 50 to 74 who smoke or recently quit will join. The goal is to see if a dedicated network makes screening easier and more effect…

This study looks back at the medical records of 300 women diagnosed with lung cancer to identify common risk factors. Researchers will examine demographics, smoking history, environmental exposures, and other potential contributors. The goal is to better understand what may drive…

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…